BioLife Solutions, Inc. (BLFS)
| Market Cap | 1.32B |
| Revenue (ttm) | 41.66M |
| Net Income (ttm) | -11.39M |
| Shares Out | 31.64M |
| EPS (ttm) | 0.12 |
| PE Ratio | 341.78 |
| Forward PE | 666.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $40.33 |
| Previous Close | $40.33 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 42.12 |
| Day's Range | 39.88 - 42.60 |
| Day's Volume | 428,919 |
| 52-Week Range | 8.36 - 45.75 |
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
BioLife Solutions, Inc.'s (BLFS) CEO Michael Rice on Q3 2020 Results - Earnings Call Transcript
BOTHELL, Wash., Nov. 5, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...
BOTHELL, Wash., Oct. 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproducti...
Q2 2020 was a stellar quarter for BLFS in terms of revenue generation and new customer onboarding.
BOTHELL, Wash., Aug. 25, 2020 /PRNewswire/ -- BioLife Solutions, Inc.
Biolife Solutions, Inc. (BLFS) CEO Michael Rice on Q2 2020 Results - Earnings Call Transcript
BOTHELL, Wash., Aug. 6, 2020 /PRNewswire/ -- BioLife Solutions, Inc.
BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BOTHELL, Wash., July 30, 2020 /PRNewswire/ -- BioLife Solutions, Inc.
BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...
BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
It doesn't look like the COVID-19 pandemic had much effect on sales of the company's bioproduction products for cell and gene therapies.
BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...
BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction...
The company experienced a 50% increase in its media revenues, although a considerable part of that is probably inflated by safety inventory building customers.
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2020 Results - Earnings Call Transcript
BOTHELL, Wash., May 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...
BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioLife Solutions' (BLFS) CEO Mike Rice on Q4 2019 Results - Earnings Call Transcript
BioLife Solutions shares opened higher before moving sharply lower Thursday despite a higher analyst price target.
BioLife's Disappointing Quarter Masks A Much Better Future
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q3 2019 Results - Earnings Call Transcript
Biolife Solutions Digesting Big Gains; More To Follow
The shares of BioLife have sold off last month, and those of competitor CryoPort much more, closing what we thought was an irrational valuation gap.
Medical Products Industry Outlook: Prospects Seem Promising
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q2 2019 Results - Earnings Call Transcript
CFO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Greef Roderick De (insider trades) sold 30,000 shares of BLFS on 08/02/2019 at an average price of $18.96 a share.
BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We noticed a huge and recent valuation gap between BioLife and CryoPort, both operating in the regenerative medicine market supplying storage media and distribution solutions.
Shares have risen by over 150% since my initial recommendation.
Both companies operate in the same market and are of similar size and produce comparable growth rates, yet CryoPort sells at 2.5x the valuation of BioLife.
We argued that the company is a ground-floor opportunity on the regenerative medicine revolution, which is just in the early innings.
Biolife Solutions' (BLFS) CEO Mike Rice on Q1 2019 Results - Earnings Call Transcript
BioLife (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
One of our top picks in the SHU portfolio is BioLife Solutions, the maker of proprietary preservation solutions for cells, tissues, and organs.
Biolife Solutions, Inc. (BLFS) CEO Michael Rice on Q4 2018 Results - Earnings Call Transcript
About BLFS
BioLife Solutions develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial an... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Nov 22, 1989 |
| CEO Michael Rice | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol BLFS |
Financial Performance
In 2019, BLFS's revenue was $27.37 million, an increase of 38.64% compared to the previous year's $19.74 million. Losses were -$1.66 million, -93.37% less than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is 44.21, which is an increase of 9.62% from the latest price.